🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Rehabilitation Methods for Unilateral Spatial Neglect in Stroke Patients

RecruitingNAAges 18 Years - 80 YearsAllFederal Center of Cerebrovascular Pathology and S…
NCT06802159 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Stroke remains one of the leading causes of mortality and disability worldwide. Between 30% and 40% of patients who have had an acute cerebral hemorrhage, develop unilateral spatial neglect syndrome (USN). USN is observed in 24% of patients with left-hemispheric stroke and 45% of patients with right-hemispheric lesions in the acute phase acute phase and in 20% of patients in the chronic phase. The presence of USN significantly complicates the rehabilitation process and negatively affects the functional outcomes. The complexity of USN correction is due to the heterogeneity of its manifestations and combination with other cognitive disorders. In 30-50% of patients with USN anosognosia is observed, in 60% - memory and attention disorders. Traditional methods of rehabilitation lead to significant improvement in 30-50% of patients with USN. The use of combined methods of treatment, includi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Normal cognitive development in accordance with age and educational level; * diagnosis with codes I63, I61 (ICD); * presence of unilateral spatial neglect syndrome in the neuropsychological status. Exclusion Criteria: * presence of mental and somatic pathology of severe degree and in decompensation stage; * the presence of gross oculomotor disorders; * presence of a sensory visual defect of moderate to severe severity
💊

What it tests

  • Conventional therapy
  • Eye tracking based therapy
  • Cognitive therapy
📍

Where

2 sites
Federal Center of Brain and Neurotechnologies of the FMBA of Russia
Moscow, Russia
Federal Center of Brain and Neurotechnologies of the FMBA of Russia
Moscow, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy